Patients who are malignant hyperthermia susceptible are often admitted overnight for observation, even after minor surgery. They may be declined care in a stand-alone day stay unit. This prospective audit set out to investigate whether patients susceptible to malignant hyperthermia can be safely treated as day stay patients.
Malignant hyperthermia (MH) is an uncommon inherited hypermetabolic disorder of skeletal muscle, triggered almost exclusively by potent inhalational anaesthetic agents and depolarizing muscle relaxants. It has an incidence of about 1:30,000 anaesthetics administered 1 . It has autosomal dominant inheritance, so 50% of subsequent generations would expect to be susceptible. with this pattern of inheritance, particularly in regions with large susceptible families, it is likely that numbers of MH susceptible individuals and patients related to MH susceptible individuals will increase. with this increase, more MH susceptible and related patients will present for day stay anaesthesia.
the feasibility of day stay anaesthesia for MH patients has been demonstrated by Yentis et al 2 . they found that a majority of children undergoing surgical procedures were admitted overnight solely for MH observation and could have been managed as day cases. Apart from this review, there is little comment in the anaesthetic literature on MH and day stay anaesthesia. we decided to undertake an audit to investigate the safety of ambulatory care in this group of patients. we also looked specifically at the issues involved with the provision of an MH day stay anaesthesia service. this paper presents additional data, including follow-up data on additional patients, to an audit previously published in this Journal: Pollock Detailed PACU monitoring was undertaken. Following transfer, a set of vital signs was documented immediately and subsequently at 15 minute intervals for four further measurements-pulse rate (PR), non-invasive blood pressure (NIBP), respiratory rate (RR) and temperature 3 . tympanic membrane temperatures were recorded using an infrared emission detector thermometer (Braun-thermoscan, which measures infrared heat generated by the tympanic membrane and auditory canal; accuracy± 0.53°C) and in the early part of the audit period (and now occasionally), a thermistor sensor (Vital-temp, a temperature probe measuring nasal core temperature; accuracy ±0.2°C). Also in the early part of the audit, a digital thermometer was used to measure axillary temperature. Continuous Spo 2 and end-tidal carbon dioxide (EtCo 2 ) measurements (Datex-ohmeda nasal sampling line) were also carried out. If stable after one hour, patients were discharged to a stepdown unit (DoSA-day of surgery admission unit, day stay only with no overnight admission) where a set of three further measurements were taken at 30-minute intervals. If the procedure was brief (e.g. middle ear ventilation tubes) the patient could be discharged at any time within this period. Arterial blood gases (ABgs) were measured only if tachycardia was sustained (120/min for 10 minutes) or temperature exceeded 38°C.
the patient and caregiver were given verbal and written advice on discharge. they were advised to contact the Duty Anaesthetist at the hospital if problems developed, particularly if a temperature greater than 38°C was recorded, or there was passage of dark urine. Follow-up by telephone was made the following day. the majority of patients lived within 70 to 80 km (90 minutes) of the hospital, although a number of muscle biopsy patients were from greater distances.
Patients were tested for MH susceptibility according to the European MH group protocol 4 . three categories of results are obtained from the in vitro contracture test: MHS (abnormal contractures to both halothane and caffeine), MHE (equivocal, responding to one agent only, regarded as susceptible until proved otherwise) and normal contractures (MHN).
Patients with MHS or MHE contracture results were included in the audit. Patients managed as MHS but subsequently diagnosed MHN were excluded from analysis. A group of patients were included who were related to MHS individuals, but had not yet been tested themselves. this was usually due to young age. these are grouped as no biopsy done (NBD). there were also a few patients from families where a causative mutation 5 (ryanodine receptor gene) had been identified. they were included if their DNA test was positive.
All patients received a trigger-free anaesthetic technique using a dedicated anaesthetic machine for general anaesthesia. the clinical management was left to the discretion of the anaesthetist, and details of anaesthetic drugs used are shown in table 1. Patients undergoing muscle biopsy with spinal anaesthesia received a 0.17% solution of bupivacaine, usually supplemented by 0.5% bupivacaine with adrenaline to the skin 6 . Bupivacaine 0.5% was usually used for epidural or spinal anaesthesia in other patients.
RESUltS
Ninety-five patients who were susceptible to MH, or related to MHS individuals required anaesthesia between November 2000 and December 2004. Seventytwo of these (75%) were managed as day stay patients. of these 72 patients, 39 were MHS patients, two were DNA positive children and one DNA positive adult, five were MHE, and 25 NBD. For all groups the age ranged from 3 to 69 years. Anaesthesia time ranged between 15 and 90 minutes (mean 47 minutes). the types of procedures are shown in Figure 1 . Muscle biopsies were the most common procedure (41%). Regional anaesthesia was used in 15% (11/72).
Intraoperative data is shown in table 2. temperatures greater than 37.5°C were recorded in two patients intraoperatively, but both had a source of sepsis (abscess). Similarly, increased EtCo 2 (>60 mmHg) was recorded during four anaesthetics but all patients were breathing spontaneously. No patient achieved an MH clinical grading scale 7 of >3 (unlikely to be MH). Higher pulse and respiratory rates were occasionally seen in younger children, but there was no other evidence of an MH reaction. table 1 indicates drugs used intraoperatively for patients undergoing general anaesthesia. All patients received propofol for induction of anaesthesia and 82% were maintained with a propofol infusion. Seventy-three per cent received an opioid such as fentanyl, alfentanil or morphine. Remifentanil was used particularly for dental procedures, especially young children requiring intubation. Prophylactic antiemetics were used in 44% (27/61), mainly 5 Ht 3 antagonists and metoclopramide. Non steroidal antiinflammatory drugs were used for pain relief in 51% of cases. table 3 indicates PACU data. three younger patients (<17 years) had pulse rates >120/min, and respiratory rates were increased (>20/min) in 9/18 of this younger group. one patient had a temperature of 37.8°C following suturing of a vaginal tear. only one patient (NBD) had an EtCo 2 >60 mmHg secondary to sedation following pain relief. An Spo 2 of 89% was recorded in a 69-year-old male following regional anaesthesia but this improved with supplemental oxygen. No patient achieved an MH clinical grading scale >3, indicating a low likelihood of an MH reaction 7 .
Nine patients remained longer than one hour in PACU, mainly due to transfer delays. two required further pain management. Complications were few -two patients with drowsiness from sedation, two with headache, two with mild hypothermia, one complaining of itchiness and two patients with brief periods of mild confusion.
there were few problems in the step-down unit (DoSA)-mild tachycardia and increased respiratory rate, particularly in young children. Several patients required pain relief with oral analgesia. two children (ENt and dental procedures), and one adult (inguinal hernia repair) were discharged from DoSA to home before the two-and-a-half hour period was complete. Attempted contact was made the following day. only forty-nine (68%) patients were able to be contacted. Seven complained of significant wound discomfort, which was mostly relieved by oral medication. one patient had a mild pyrexia, three vomited following discharge and there were several mild complaints such as dizziness, neck pain, itchiness and tiredness. No patient had symptoms suggesting an MH reaction. the intraoperative and PACU data was included in about 35% of patients in a previous study but follow-up post discharge was more detailed in the current study and has not been published previously 3 .
DISCUSSIoN
MH susceptible patients often require procedures that can be managed as day stay. Before this audit commenced, a retrospective review of day stay MHS/related patients with age range 1 to 75 years was first undertaken (N. McDonnell-unpublished data). Patients were identified from the Palmerston North MH database between 1991 and late 2000, and intraoperative and PACU data was obtained from reviewing old records. this demonstrated few complications and no MH reactions. However the fact that no reaction was observed does not mean that one cannot occur. Using the principles of inferential statistics that apply to zero numerators 8 , this review of 152 procedures suggested that the possibility of an MH reaction occurring, within 95% confidence limits, is less than 2.0%. However, larger numbers will be required to reduce that risk to less than 1%. this small ongoing prospective audit attempts to demonstrate that day stay anaesthesia in MH patients is safe.
the increased popularity of day stay surgery is primarily explained by its substantial cost saving. However, convenience and acceptance by patients are other significant factors. It has been made possible by advances in surgical techniques and equipment, recent introduction of anaesthetic drugs more suited to day stay anaesthesia and advances in anaesthesia equipment. Day surgery demands high quality anaesthesia characterized by maximal safety, minimal sideeffects and rapid discharge 9, 10 .
Patients at increased risk include those who are MH susceptible by investigation, uninvestigated relatives of an MHS/susceptible patient, and occasionally a patient with a history of possible MH in him-or herself or a relative. All possible MH susceptible patients for elective surgery, including day stay procedures, should be seen at an anaesthetic preassessment clinic. this gives an opportunity to confirm susceptibility, review old notes and discuss the anaesthetic technique. A previous normal anaesthetic does not exclude MH susceptibility. Patients who are MHS/E by in vitro contracture test are regarded as susceptible. MHN or negative results are reliable and these patients and their offspring can be administered triggering agents safely if required. A positive DNA test indicates MH susceptibility. A negative DNA test must be confirmed by a negative in vitro contracture test, as more than one mutation appears to be present in a few families. Such patients must be treated as susceptible until this test has been performed.
Airway assessment is important, as methods of intubation without the use of suxamethonium need to be considered. Stress is a potential trigger and premedication is usually recommended. However day case procedures in general are not lengthy and premedication may delay discharge. In our experience, omission of premedication has not reduced the safety of anaesthesia in this institution.
Day stay anaesthesia requires an anaesthetic technique that is associated with a rapid recovery of postoperative cognitive function and a minimal incidence of side-effects such as nausea and vomiting. the management of MH susceptible patients requiring general anaesthesia has been simplified by the availability of total intravenous anaesthesia with agents such as propofol and remifentanil, with short onset and duration of effect, and associated technology such as the Diprifusor™. the pharmacokinetic and pharmacodynamic properties of these agents are also ideal for use in day stay anaesthesia 9, [11] [12] [13] [14] . Propofol induction with or without an infusion for maintenance anaesthesia was used in all cases undergoing general anaesthesia (table 1). the use of propofol results in rapid recovery, enabling early discharge from the PACU area 15 . Remifentanil, an esterase-metabolized opioid, provides a short and predictable duration of analgesic effect without any accumulation when administered by continuous infusion 16 .
Regional anaesthesia was used in only 15% of patients in this audit. A greater number of patients may have been expected to receive regional techniques, but 41% of patients were for muscle biopsies for in vitro contracture test. the majority of these came from outside the region. Patient choice is a major factor in this decision but same-day home discharge is permissible if the patient is accompanied. It is thought advisable to give general anaesthesia with propofol, nonsteroidal anti-inflammatory drugs, with or without a small dose of opioid, rather than risk a post spinal puncture headache in a patient discharged to a distant area.
MH patients having regional anaesthesia are now treated in the PACU as normal (non MH) patients. Both amide and ester local anaesthetic drugs are safe to use in MH susceptible patients. A dilute solution of spinal bupivacaine is used to effect rapid discharge. Plain bupivacaine 0.5% is diluted to 0.17% by adding 2 ml normal saline to 1 ml of solution 6 . this provides sufficient anaesthesia for muscle excision and in the interests of time, superficial anaesthesia is supplemented by 0.5% bupivacaine with adrenaline. the duration of the spinal is about 90 minutes.
Prophylactic dantrolene is not required. It may be associated with significant side-effects. the safety of omission has been demonstrated in a number of publications [17] [18] [19] and it has not been used in this institution for many years. A patient who has had a previous MH episode does not require overnight admission.
there are some essential requirements for anaesthesia in MH patients at day surgery facilities as there is a remote risk of a stress induced MH reaction 3 . Dantrolene must be immediately available within five minutes of the operating site (200 mg, i.e. 10 vials). Resuscitation drugs and equipment should be readily available including insulin, glucose, antiarrhythmics and methods of cooling. there should be laboratory access for electrolytes and arterial blood gases within 10 minutes of the operating theatre and personnel available for support such as mixing up dantrolene, assistance with young children and management in the PACU. A ventilated theatre and clean equipment should have been prepared and access to an intensive care unit (ICU) must be available.
the requirements can be achieved in hospitals with or without an ICU but they must have laboratory facilities and immediate transport available to a hospital with an ICU. the limiting factor for a private hospital may be distance to other facilities. Equipment, personnel and monitoring to treat complications must be available where any general anaesthesia is undertaken, and this may be the limiting factor for dental surgeries or surgeons' offices 20 , although local anaesthesia with sympathomimetics can be safely undertaken in dental surgeries. general anaesthesia in MH susceptible patients is not undertaken in dental surgeries in this region.
Patients who are at risk of MH need appropriate postoperative monitoring in PACU. MH reactions can become apparent in PACU. when reported these have usually been within one hour of transfer to PACU [21] [22] [23] [24] . traditionally, four hours close observation has been recommended 25 . our retrospective review and ongoing audit 3 has shown that monitoring in PACU for one hour is safe.
Early discharge is the hallmark of day stay surgery. this can be delayed if prolonged monitoring is required. this audit has shown that patients can be discharged two-and-one-half hours after surgery without complication. However, they should be closely observed in the first hour with continuous monitoring as described. written instructions on discharge are important so that the patient and caregiver have clear guidelines on which signs are significant. Followup the next day is carried out by day stay or PACU nursing staff. A summary of procedures undertaken at this hospital is presented in table 4. Seventy-two MH susceptible patients were day stay, of whom 11 had regional anaesthesia. Using the principles of inferential statistics that apply to zero numerators 8 on the remaining 61, this leaves us with a 4.9% possibility within 95% confidence limits that an MH reaction could occur, given sufficient numbers. ongoing audit with increased numbers of patients may reduce this further.
Although numbers are as yet small, we have shown that MH susceptible patients can be safely treated as day stay patients in this institution. the key factors are an appropriate surgical facility, close monitoring immediately after anaesthesia and clear instructions to caregivers.
(Massey University), hospital-based scientist for his contribution to diagnosis of MH susceptibility using the in vitro contracture test.
